2026-06-14T03:53:08Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/167802024-09-27T08:46:01Zcom_20.500.12105_19604com_20.500.12105_2051col_20.500.12105_19605

00925njm 22002777a 4500 dc Lalaguna, Laura author Ramos-Hernandez, Laura author Priori, Silvia G. author Lara-Pezzi, Enrique author 2023 Inherited arrhythmic disorders are a group of heterogeneous diseases predisposing to life-threatening arrhythmias and sudden cardiac death. Their diagnosis is not always simple due to incomplete penetrance and genetic heterogeneity. Furthermore, the available treatments are usually invasive and merely preventive. Genome editing and especially CRISPR/Cas9 technologies have the potential to correct the genetic arrhythmogenic substrate, thereby offering a cure for these fatal diseases. To date, genome editing has allowed reproducing cardiac arrhythmias in vitro, providing a robust platform for variant pathogenicity, mechanistic, and drug-testing studies. However, in vivo approaches still need profound research regarding safety, specificity, and efficiency of the methods. Adv Exp Med Biol . 2023:1396:115-127. 10.1007/978-981-19-5642-3_8 0065-2598 Advances in experimental medicine and biology 36454463 http://hdl.handle.net/20.500.12105/16780 Genome Editing and Inherited Cardiac Arrhythmias.